CN111671791A - Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof - Google Patents
Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof Download PDFInfo
- Publication number
- CN111671791A CN111671791A CN202010447940.0A CN202010447940A CN111671791A CN 111671791 A CN111671791 A CN 111671791A CN 202010447940 A CN202010447940 A CN 202010447940A CN 111671791 A CN111671791 A CN 111671791A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactobacillus
- composition
- oligosaccharide
- prebiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 206010010774 Constipation Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 230000000968 intestinal effect Effects 0.000 title abstract description 21
- 230000008685 targeting Effects 0.000 title abstract description 5
- 239000006041 probiotic Substances 0.000 claims abstract description 40
- 235000018291 probiotics Nutrition 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 29
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 28
- 210000000582 semen Anatomy 0.000 claims abstract description 20
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 16
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 16
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 16
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 16
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 16
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 16
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 13
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 13
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 11
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 11
- 229940029339 inulin Drugs 0.000 claims abstract description 11
- 241000218236 Cannabis Species 0.000 claims abstract description 9
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 9
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 9
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 8
- 229920001353 Dextrin Polymers 0.000 claims abstract description 8
- 239000004375 Dextrin Substances 0.000 claims abstract description 8
- 235000019425 dextrin Nutrition 0.000 claims abstract description 8
- 241000193749 Bacillus coagulans Species 0.000 claims abstract description 7
- 229940054340 bacillus coagulans Drugs 0.000 claims abstract description 7
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 6
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 5
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 4
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 4
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 4
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 4
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 4
- 240000008669 Hedera helix Species 0.000 claims abstract description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 14
- 230000000529 probiotic effect Effects 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 240000002853 Nelumbo nucifera Species 0.000 claims description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 229940126680 traditional chinese medicines Drugs 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 235000007215 black sesame Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000194018 Streptococcaceae Species 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- -1 compound diphenoxylate Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000408944 Clostridium putrefaciens Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000046198 Triteleia hyacinthina Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000019680 high-energy food Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a microecological composition for improving constipation by targeting intestinal flora and a preparation thereof, wherein the microecological composition comprises probiotics, prebiotics and a medicine-food homologous traditional Chinese medicine, wherein the probiotics are selected from the following components: at least one of bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus paracasei and bacillus coagulans; the prebiotics are selected from: at least one of stachyose, fructo-oligosaccharide, isomaltooligosaccharide, galacto-oligosaccharide, inulin, resistant dextrin or xylo-oligosaccharide; the medicine and food homologous Chinese medicine is selected from: at least one of semen Sesami Niger, semen Cassiae, fructus Cannabis, Mel, semen lablab album, Coicis semen, Poria or folium Nelumbinis. The microecological composition can effectively regulate intestinal microecology in a targeted manner, and finally achieves the purpose of improving constipation.
Description
Technical Field
The invention relates to the technical field of microecological preparations, in particular to a microecological composition for improving constipation by targeting intestinal flora and a preparation thereof.
Background
With the change of dietary structure and the increase of mental and social pressure, constipation becomes one of the main problems troubling modern people, and the quality of life of people is seriously influenced. At present, the constipation treatment measures mainly comprise western medicines and traditional Chinese medicines, and the effects of the traditional Chinese medicines are mainly to change the intestinal osmotic pressure to force water to transfer into the intestinal tract or force the intestinal tract to defecate, so that the constipation symptom is temporarily relieved. However, this treatment is prone to dependency and may have major side effects.
In recent years, many studies have found that disorder of intestinal flora is closely related to occurrence and development of constipation. Compared with a healthy control group, the species abundance of flora and shannon diversity index in intestinal tracts of constipation patients are obviously reduced, the number of beneficial bacteria such as bifidobacteria, lactic acid bacteria and methanogens is obviously reduced, and the data of conditional pathogenic bacteria such as clostridium putrefaciens are obviously improved. This suggests that disturbance of the intestinal flora may be one of the most important factors in inducing constipation. Therefore, targeting the gut flora to balance and regulate its structure would be an effective means to ameliorate constipation.
At present, diseases such as obesity, hyperglycemia, diabetes and the like caused by excessive intake of high-energy foods such as sucrose, fat and the like become a problem of increasing social attention. The digestion and absorption of prebiotics such as fructo-oligosaccharide, stachyose, inulin and galacto-oligosaccharide are independent of the change of insulin without causing the change of blood sugar, and can be eaten by hyperglycemia, obesity or diabetes patients. The medicinal and edible traditional Chinese medicines such as cassia seeds, fructus cannabis and the like are rich in a large amount of dietary fibers and less starch, and belong to low-GI food materials. A large number of researches prove that the probiotics are beneficial to losing weight and improving the conditions of hyperglycemia and the like.
Disclosure of Invention
The first aspect of the invention aims to provide a microecological composition which can improve the intestinal flora structure of a body in a targeted manner and improve constipation.
In a second aspect, the present invention provides a constipation-improving microecological preparation comprising the above composition.
The technical scheme adopted by the invention is as follows:
in a first aspect of the present invention, there is provided a micro-ecological composition, comprising the following raw materials in parts by weight per 100 parts of the composition: 5-75 parts of probiotics, 20-90 parts of prebiotics and 1-45 parts of medicinal and edible traditional Chinese medicine;
wherein the probiotic is selected from: at least one of bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus paracasei and bacillus coagulans;
the prebiotics are selected from: at least one of stachyose, fructo-oligosaccharide, isomaltooligosaccharide, galacto-oligosaccharide, inulin, resistant dextrin or xylo-oligosaccharide;
the medicinal and edible traditional Chinese medicine is selected from: at least one of semen Sesami Niger, semen Cassiae, fructus Cannabis, Mel, semen lablab album, Coicis semen, Poria or folium Nelumbinis.
Preferably, according to the composition of the first aspect of the invention, the probiotic is selected from: at least one of Bifidobacterium animalis, Bifidobacterium adolescentis, Bifidobacterium longum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus plantarum or Bacillus coagulans;
the prebiotics are selected from: one or more of stachyose, fructo-oligosaccharide, galacto-oligosaccharide, inulin or resistant dextrin. More preferably at least one of stachyose, inulin or galacto-oligosaccharide;
the medicinal and edible traditional Chinese medicine is selected from: at least one of semen Sesami Niger, semen Cassiae, fructus Cannabis, Mel or folium Nelumbinis.
More preferably, according to the composition of the first aspect of the invention, the probiotic is selected from: at least one of bifidobacterium animalis, bifidobacterium adolescentis, lactobacillus rhamnosus or lactobacillus acidophilus;
the prebiotics are selected from: at least one of stachyose, fructo-oligosaccharide, galacto-oligosaccharide, inulin and resistant dextrin;
the medicinal and edible traditional Chinese medicine is selected from: at least one of cassia seed, fructus cannabis or lotus leaf.
Still further according to the composition of the first aspect of the invention, the probiotic is bifidobacterium animalis, lactobacillus adolescentis, lactobacillus acidophilus and lactobacillus rhamnosus;
the prebiotics are stachyose and galacto-oligosaccharide;
the medicine and food homologous traditional Chinese medicine is semen cassiae.
Preferably, the composition according to the first aspect of the present invention comprises the following raw materials in parts by weight per 100 parts of the composition: 5-70 parts of probiotics, 20-85 parts of prebiotics and 1-30 parts of medicinal and edible traditional Chinese medicine.
Preferably, the composition according to the first aspect of the present invention comprises the following raw materials in parts by weight per 100 parts of the composition: 5-70 parts of probiotics, 20-70 parts of prebiotics and 10-25 parts of medicinal and edible traditional Chinese medicine.
More preferably, the composition according to the first aspect of the present invention comprises the following raw materials in parts by weight per 100 parts of the composition: 25 parts of probiotics, 60 parts of prebiotics and 15 parts of medicinal and edible traditional Chinese medicine.
Preferably, the composition according to the first aspect of the present invention comprises 1 × 10 parts per 100 parts of the composition6～1 ×1011Probiotic bacteria of CFU.
More preferably, the composition according to the first aspect of the present invention comprises 1 × 10 parts per 100 parts of the composition6～ 1×1011Probiotic bacteria of CFU.
Further preferably, according to the first aspect of the present inventionComposition comprising 1 × 10 per 100 parts of said composition8～5×1010Probiotic bacteria of CFU.
In a second aspect of the present invention, there is provided a micro-ecological preparation for relieving constipation, comprising the composition according to the first aspect of the present invention.
Further, the preparation according to the second aspect of the present invention further comprises pharmaceutically acceptable excipients.
The invention has the beneficial effects that:
1. the microecological preparation provided by the invention can regulate intestinal flora in a targeted manner, and on one hand, the probiotics and the prebiotics are supplemented, so that the quantity of beneficial bacteria in the intestinal tract is increased, the growth of harmful bacteria is inhibited, and the intestinal microecology of the organism is recovered. On the other hand, the active ingredients of the medicine and food homologous traditional Chinese medicine can promote the recovery of intestinal mucosa and intestinal barrier, reduce the intake of harmful ingredients, improve the self-regulation capability of the organism and finally achieve the purpose of improving constipation.
2. The probiotics, the prebiotics and the medicinal and edible traditional Chinese medicine have synergistic effect, and on one hand, the probiotics can utilize the polysaccharide or dietary fiber in the prebiotics and the medicinal and edible traditional Chinese medicine to grow or proliferate. On the other hand, prebiotics or dietary fibers can be fermented into short chain fatty acids by probiotics to promote intestinal microecological self-regulation. Meanwhile, the probiotics can also improve the utilization rate of active ingredients of the medicine-food homologous traditional Chinese medicine and improve the flavor of the medicine-food homologous traditional Chinese medicine.
3. The raw materials selected by the invention are all low-calorie components, and low-GI components or components independent of insulin are selected as the standard for formula research and development, so that healthy products without influence on blood sugar are beneficial to avoiding the influence on the blood sugar.
Drawings
FIG. 1 shows the first time of dark stool of rats in different groups.
FIG. 2 Small intestine ink propulsion rates for different groups of rats.
FIG. 3 small intestine physiological section of different groups of rats.
FIG. 4 shows intestinal flora structure (phylum level) of different groups of rats.
FIG. 5 intestinal flora structure (family level) of different groups of rats.
Detailed Description
The invention is further illustrated by the following specific examples. The following examples are for illustrative purposes only and are not to be construed as limiting the invention. Unless otherwise specified, the raw materials used in the following examples, raw materials for reagents, were raw materials conventionally commercially available or commercially available. The apparatus used in the following examples is an apparatus conventionally used in the art unless otherwise specified.
Example 1
A micro-ecological solid beverage comprising, per 100 parts dry weight of solid beverage: 25 parts of probiotics (bifidobacterium animalis, lactobacillus adolescentis, lactobacillus acidophilus and lactobacillus rhamnosus), 60 parts of prebiotics (stachyose and galactooligosaccharide) and 15 parts of medicine-food homologous traditional Chinese medicine (cassia seed).
Example 2
A microecological formulation comprising, per 100 parts dry weight of the tablet: 5 parts of probiotics (bifidobacterium animalis, lactobacillus adolescentis, lactobacillus acidophilus and lactobacillus rhamnosus), 70 parts of prebiotics (stachyose and galactooligosaccharide) and 25 parts of medicine-food homologous traditional Chinese medicine (cassia seed).
Example 3
A micro-ecological beverage comprising, per 100 parts of beverage by weight: 70 parts of probiotics (bifidobacterium animalis, lactobacillus adolescentis, lactobacillus acidophilus and lactobacillus rhamnosus), 20 parts of prebiotics (stachyose and galactooligosaccharide) and 10 parts of medicine-food homologous traditional Chinese medicine (cassia seed).
Example 4
A microecological formulation comprising, per 100 parts dry weight of the tablet: 40 parts of probiotics (bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus paracasei and bacillus coagulans), 50 parts of prebiotics (stachyose, resistant dextrin or xylo-oligosaccharide), and 20 parts of medicine-food homologous traditional Chinese medicines (honey, white hyacinth bean, coix seed, poria cocos and lotus leaf).
Example 5
A microecological formulation comprising, per 100 parts dry weight of the tablet: 50 parts of probiotics (bifidobacterium animalis, lactobacillus reuteri, bacillus coagulans and lactobacillus rhamnosus), 35 parts of prebiotics (fructo-oligosaccharide, isomaltooligosaccharide, galacto-oligosaccharide and inulin) and 20 parts of medicinal and edible traditional Chinese medicines (fructus cannabis, semen cassiae and black sesame).
Example 6
In this example, 30 SD rats of 5-6 weeks old were selected and randomly divided into 3 groups (normal group CON, model group MOD, treatment group PRO) after 1 week of adaptive feeding using the probiotic described in example 1 as the experimental material.
The compound diphenoxylate tablets with the weight of 20mg/kg are intragastrically administered to the model group and the treatment group every day from the 2 nd week, the preparation with the weight of 0.4g/kg is intragastrically administered to the treatment group every day from the 3 rd week, the same amount of PBS solution is intragastrically administered to the normal group, the first defecation time is measured every week, the small intestine ink propulsion rate is measured at the end of the 7 th week, and the HE staining of the colon proximal tissue is obtained to observe the pathological characteristics, and the results are shown in the attached figures 1 to 3.
As can be seen from the attached figure 1, the first grain stool time of the preparation treatment group has no significant difference with that of the normal group, and is significantly reduced compared with the model group.
As can be seen from FIG. 2, the small intestine propulsion rate of the formulation treatment group is significantly different from that of the normal group, and is significantly increased compared with that of the model group.
As can be seen from FIG. 3, the small intestine tissue of the treatment group of example 1 has no significant difference from the normal group, while the mucosal epithelium of the model group is necrotically exfoliated and the lamina propria is infiltrated with a small amount of lymphocytes.
Example 7
In this example, 30 SD rats of 5-6 weeks old were selected and randomly divided into 3 groups (normal group CON, model group MOD, probiotic group PRO) after 1 week of adaptive feeding using the probiotic described in example 3 as experimental material.
The compound diphenoxylate tablets with the weight of 20mg/kg are gavaged every day in the model group and the treatment group from the 2 nd week, the preparation with the weight of 0.4g/kg is gavaged every day in the treatment group from the 3 rd week, the PBS solution with the same weight is gavaged in the normal group, the content in the cecum bag is collected at the end of the 7 th week for 16S rRNA microbial sequencing, and the results of sequencing analysis are shown in figures 4 and 5.
FIG. 4 shows that the actinomycetemcomia was significantly elevated in the model group compared to the normal group (P < 0.05), indicating an imbalance in the intestinal flora in the constipation model group. Compared with a model group, the actinomycetes of the preparation treatment group is obviously reduced (P is less than 0.05), and is lower than that of a normal group, but the actinomycetes of the preparation treatment group has no significant difference.
FIG. 5 shows that AKK family is significantly decreased and that digestive streptococcaceae family is significantly increased in the model group compared to the normal group. Whereas the group of preparations in example 3 showed a significant decrease in the digestive streptococcaceae family and a significant increase in the lactobacillaceae family. The microecological preparation in the embodiment 3 can adjust intestinal flora in a targeted manner, and on one hand, the probiotics and the prebiotics are supplemented, so that the quantity of beneficial bacteria in the intestinal tract is increased, the growth of harmful bacteria is inhibited, and the intestinal microecology of the organism is recovered.
A control experiment was designed to replace certain component(s) resulting in significant differences in results.
Comparative example 1
A microecological formulation comprising, per 100 parts dry weight of the tablet: 30 parts of probiotics (bifidobacterium animalis (inactivated) and lactobacillus rhamnosus (inactivated)), 30 parts of microcrystalline cellulose and 40 parts of medicinal and edible traditional Chinese medicines (cassia seeds and black sesame).
The Bifidobacterium animalis and Lactobacillus rhamnosus in the preparation are inactivated. A great deal of research by the inventor proves that the cell wall of the inactivated probiotics contains a great amount of active ingredients, which is helpful for enhancing the immunity of the organism, but no report about the capability of the inactivated probiotics to promote the recovery of the intestinal flora structure and improve constipation exists.
Microcrystalline cellulose is commonly used in the fields of pharmacy and food, has no toxic effect on the body basically, but reports about constipation improvement.
The medicinal and edible traditional Chinese medicines (semen cassiae and black sesame) are beneficial to relieving constipation and promoting defecation, but the action and effect are not obvious.
Therefore, the effect of improving constipation by using the preparation in this example is not significant, and is significantly reduced compared to the preparations in other examples.
In conclusion, the results show that the microecological preparation in the embodiment is used for targeted adjustment of the intestinal flora structure and the intestinal microecological balance, so that the first defecation time is effectively shortened, the small intestine propulsion rate is increased, and the intestinal tissue health is maintained, thereby indicating that the microecological preparation has an effective constipation improving effect.
Claims (10)
1. The microecological composition comprises the following raw materials in parts by weight per 100 parts of the composition: 5-75 parts of probiotics, 20-90 parts of prebiotics and 1-45 parts of medicinal and edible traditional Chinese medicine;
wherein the probiotic is selected from: at least one of bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus paracasei and bacillus coagulans;
the prebiotics are selected from: at least one of stachyose, fructo-oligosaccharide, isomaltooligosaccharide, galacto-oligosaccharide, inulin, resistant dextrin or xylo-oligosaccharide;
the medicinal and edible traditional Chinese medicine is selected from: at least one of semen Sesami Niger, semen Cassiae, fructus Cannabis, Mel, semen lablab album, Coicis semen, Poria or folium Nelumbinis.
2. The composition according to claim 1, characterized in that the probiotic bacteria are selected from: at least one of Bifidobacterium animalis, Bifidobacterium adolescentis, Bifidobacterium longum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus plantarum or Bacillus coagulans;
the prebiotics are selected from: one or more of stachyose, fructo-oligosaccharide, galacto-oligosaccharide, inulin and resistant dextrin;
preferably at least one of stachyose, inulin or galacto-oligosaccharides;
the medicinal and edible traditional Chinese medicine is selected from: at least one of semen Sesami Niger, semen Cassiae, fructus Cannabis, Mel or folium Nelumbinis.
3. The composition according to claim 2, characterized in that the probiotic bacteria are selected from: at least one of bifidobacterium animalis, bifidobacterium adolescentis, lactobacillus rhamnosus or lactobacillus acidophilus;
the prebiotics are selected from: at least one of stachyose, fructo-oligosaccharide, galacto-oligosaccharide, inulin and resistant dextrin;
the medicinal and edible traditional Chinese medicine is selected from: at least one of cassia seed, fructus cannabis or lotus leaf.
4. The composition according to claim 3, characterized in that the probiotic bacteria are Bifidobacterium animalis, Lactobacillus adolescentis, Lactobacillus acidophilus and Lactobacillus rhamnosus;
the prebiotics are stachyose and galacto-oligosaccharide;
the medicine and food homologous traditional Chinese medicine is semen cassiae.
5. The composition according to claim 4, wherein the composition comprises the following raw materials in parts by weight per 100 parts of the composition: 5-70 parts of probiotics, 20-70 parts of prebiotics and 10-25 parts of medicinal and edible traditional Chinese medicine.
6. The composition according to claim 5, wherein the composition comprises the following raw materials in parts by weight per 100 parts of the composition: 25 parts of probiotics, 60 parts of prebiotics and 15 parts of medicinal and edible traditional Chinese medicine.
7. Composition according to any one of claims 1 to 6, characterized in that it comprises 1 × 10 per 100 parts of said composition6～1×1011Probiotic bacteria of CFU.
8. The composition of claim 7, wherein said composition comprises 1 × 10 per 100 parts of said composition8～5×1010Probiotic bacteria of CFU.
9. A microecological preparation for ameliorating constipation, which comprises the composition according to any one of claims 1 to 8.
10. The formulation of claim 9, further comprising a pharmaceutically acceptable excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010447940.0A CN111671791A (en) | 2020-05-25 | 2020-05-25 | Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010447940.0A CN111671791A (en) | 2020-05-25 | 2020-05-25 | Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111671791A true CN111671791A (en) | 2020-09-18 |
Family
ID=72434783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010447940.0A Pending CN111671791A (en) | 2020-05-25 | 2020-05-25 | Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111671791A (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112370470A (en) * | 2020-11-18 | 2021-02-19 | 复旦大学附属中山医院 | Microecological preparation for reconstructing intestinal microecology |
| CN112516265A (en) * | 2020-12-16 | 2021-03-19 | 青岛颐圣康和生物制药有限公司 | Probiotic Chinese herbal medicine compound composition for relaxing bowels and application thereof |
| CN112841661A (en) * | 2021-02-01 | 2021-05-28 | 贵州菊春堂农业科技发展有限公司 | Preparation method of chrysanthemum prebiotics |
| CN113080470A (en) * | 2021-04-13 | 2021-07-09 | 苏州赛迈尔生物科技有限公司 | Composition beneficial to intestinal regulation and preparation method thereof |
| CN113151056A (en) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | Probiotic composition, preparation method and application thereof |
| CN113713080A (en) * | 2021-07-09 | 2021-11-30 | 武汉自然萃创新科技有限公司 | Probiotic honey dew |
| CN113717293A (en) * | 2021-08-09 | 2021-11-30 | 中山大学 | Soft coral polysaccharide, and preparation method and application thereof |
| CN114158735A (en) * | 2021-12-06 | 2022-03-11 | 青岛东海药业有限公司 | Probiotic composition and application thereof |
| CN114504623A (en) * | 2022-04-19 | 2022-05-17 | 广东益可维生物技术有限公司 | Traditional Chinese medicine probiotic composite product for improving qi deficiency type constipation and preparation method thereof |
| CN114525233A (en) * | 2022-04-22 | 2022-05-24 | 中国疾病预防控制中心传染病预防控制所 | Application of lactobacillus sake and stachyose composition in preparation of medicine for treating constipation |
| CN114806930A (en) * | 2022-03-31 | 2022-07-29 | 青岛东海药业有限公司 | Probiotic composition and application thereof |
| CN114831286A (en) * | 2022-05-30 | 2022-08-02 | 天津小薇生物科技有限公司 | Composition with constipation relieving function and preparation method thereof |
| CN114984130A (en) * | 2022-06-30 | 2022-09-02 | 大连医科大学 | Composition of probiotics and medicinal and edible materials and preparation method and application thereof |
| CN114984059A (en) * | 2022-05-05 | 2022-09-02 | 宁夏医科大学 | Anti-colorectal cancer probiotic preparation and preparation method and application thereof |
| CN115068509A (en) * | 2021-03-12 | 2022-09-20 | 湖南补天药业股份有限公司 | Pharmaceutical composition containing high-substitution-degree carboxymethyl pachyman and application thereof |
| CN115177632A (en) * | 2022-04-25 | 2022-10-14 | 承葛健康科技(广东)有限公司 | Prebiotic composition with constipation relieving effect |
| CN115844012A (en) * | 2022-11-24 | 2023-03-28 | 浙江工业大学 | Composition with constipation relieving function, preparation method and equipment |
| CN116803300A (en) * | 2023-05-12 | 2023-09-26 | 黑龙江飞鹤乳业有限公司 | Synbiotic composition capable of improving chronic constipation symptom and preparation method and application thereof |
| CN117122002A (en) * | 2023-09-11 | 2023-11-28 | 辅农(廊坊)生物科技有限公司 | Solid beverage for improving intestinal flora and preparation method thereof |
| CN118592617A (en) * | 2024-07-31 | 2024-09-06 | 内蒙古兰格格乳业有限公司 | Composition for treating and/or improving functional constipation and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103431376A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for constipation patients |
| CN103908585A (en) * | 2013-01-05 | 2014-07-09 | 吴炳新 | Probiotic fermentation composition used for preventing and treating constipation |
| US20140228431A1 (en) * | 2002-05-20 | 2014-08-14 | Cedars-Sinai Medical Center | Method of treating constipation |
| CN106265876A (en) * | 2016-10-14 | 2017-01-04 | 青岛自然珍萃生物科技有限公司 | A kind of probiotic composition and the application in alleviation or treatment constipation thereof |
| CN109170909A (en) * | 2018-10-10 | 2019-01-11 | 河北畅然生物科技有限公司 | A kind of compound probiotic and prebiotic compositions and preparation method thereof improving constipation |
| CN109430851A (en) * | 2018-12-26 | 2019-03-08 | 广州普维君健药业有限公司 | Relaxing bowels to lose weight composition and its preparation method and application |
| CN110338402A (en) * | 2018-04-08 | 2019-10-18 | 王康学 | A kind of compound probiotic powder and preparation method thereof |
-
2020
- 2020-05-25 CN CN202010447940.0A patent/CN111671791A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140228431A1 (en) * | 2002-05-20 | 2014-08-14 | Cedars-Sinai Medical Center | Method of treating constipation |
| CN103908585A (en) * | 2013-01-05 | 2014-07-09 | 吴炳新 | Probiotic fermentation composition used for preventing and treating constipation |
| CN103431376A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for constipation patients |
| CN106265876A (en) * | 2016-10-14 | 2017-01-04 | 青岛自然珍萃生物科技有限公司 | A kind of probiotic composition and the application in alleviation or treatment constipation thereof |
| CN110338402A (en) * | 2018-04-08 | 2019-10-18 | 王康学 | A kind of compound probiotic powder and preparation method thereof |
| CN109170909A (en) * | 2018-10-10 | 2019-01-11 | 河北畅然生物科技有限公司 | A kind of compound probiotic and prebiotic compositions and preparation method thereof improving constipation |
| CN109430851A (en) * | 2018-12-26 | 2019-03-08 | 广州普维君健药业有限公司 | Relaxing bowels to lose weight composition and its preparation method and application |
Non-Patent Citations (7)
| Title |
|---|
| XXXXXXXX569: "安贝适益生菌", 《360百科》 * |
| 中国农村技术开发中心，国家新食品资源健康产业技术创新战略联盟: "《舌尖上的新食品》", 31 March 2016, 中国轻工业出版社 * |
| 卢卫红: "《功能性食品与中国药膳》", 31 October 2009, 哈尔滨工业大学出版社 * |
| 杨远志等: "益生菌和益生元在功能性食品中的应用现状及展望", 《中国食品添加剂》 * |
| 甘智荣: "《绝对"豆"美食》", 31 December 2016, 黑龙江科学技术出版社 * |
| 邵国杰: "《神奇本草》", 31 May 2019, 中国中医药出版社 * |
| 黄龙: "《特医食品的开发与精益制造》", 31 August 2019, 华东理工大学出版社 * |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112370470A (en) * | 2020-11-18 | 2021-02-19 | 复旦大学附属中山医院 | Microecological preparation for reconstructing intestinal microecology |
| CN112370470B (en) * | 2020-11-18 | 2023-05-26 | 复旦大学附属中山医院 | Microecological preparation for reconstructing intestinal microecology |
| CN112516265A (en) * | 2020-12-16 | 2021-03-19 | 青岛颐圣康和生物制药有限公司 | Probiotic Chinese herbal medicine compound composition for relaxing bowels and application thereof |
| CN112516265B (en) * | 2020-12-16 | 2022-06-21 | 青岛琛蓝生物营养技术有限公司 | Probiotic Chinese herbal medicine compound composition for relaxing bowels and application thereof |
| CN112841661A (en) * | 2021-02-01 | 2021-05-28 | 贵州菊春堂农业科技发展有限公司 | Preparation method of chrysanthemum prebiotics |
| CN115068509A (en) * | 2021-03-12 | 2022-09-20 | 湖南补天药业股份有限公司 | Pharmaceutical composition containing high-substitution-degree carboxymethyl pachyman and application thereof |
| CN113151056A (en) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | Probiotic composition, preparation method and application thereof |
| CN113080470A (en) * | 2021-04-13 | 2021-07-09 | 苏州赛迈尔生物科技有限公司 | Composition beneficial to intestinal regulation and preparation method thereof |
| CN113713080A (en) * | 2021-07-09 | 2021-11-30 | 武汉自然萃创新科技有限公司 | Probiotic honey dew |
| CN113717293A (en) * | 2021-08-09 | 2021-11-30 | 中山大学 | Soft coral polysaccharide, and preparation method and application thereof |
| CN114158735A (en) * | 2021-12-06 | 2022-03-11 | 青岛东海药业有限公司 | Probiotic composition and application thereof |
| CN114158735B (en) * | 2021-12-06 | 2024-05-31 | 青岛东海药业有限公司 | Probiotic composition and application thereof |
| CN114806930A (en) * | 2022-03-31 | 2022-07-29 | 青岛东海药业有限公司 | Probiotic composition and application thereof |
| CN114504623A (en) * | 2022-04-19 | 2022-05-17 | 广东益可维生物技术有限公司 | Traditional Chinese medicine probiotic composite product for improving qi deficiency type constipation and preparation method thereof |
| CN114525233A (en) * | 2022-04-22 | 2022-05-24 | 中国疾病预防控制中心传染病预防控制所 | Application of lactobacillus sake and stachyose composition in preparation of medicine for treating constipation |
| CN114525233B (en) * | 2022-04-22 | 2022-07-22 | 中国疾病预防控制中心传染病预防控制所 | Application of lactobacillus sake and stachyose composition in preparation of medicine for treating constipation |
| CN115177632A (en) * | 2022-04-25 | 2022-10-14 | 承葛健康科技(广东)有限公司 | Prebiotic composition with constipation relieving effect |
| CN114984059A (en) * | 2022-05-05 | 2022-09-02 | 宁夏医科大学 | Anti-colorectal cancer probiotic preparation and preparation method and application thereof |
| CN114831286A (en) * | 2022-05-30 | 2022-08-02 | 天津小薇生物科技有限公司 | Composition with constipation relieving function and preparation method thereof |
| CN114831286B (en) * | 2022-05-30 | 2023-09-26 | 天津小薇生物科技有限公司 | Composition with constipation relieving function and preparation method thereof |
| CN114984130A (en) * | 2022-06-30 | 2022-09-02 | 大连医科大学 | Composition of probiotics and medicinal and edible materials and preparation method and application thereof |
| CN115844012A (en) * | 2022-11-24 | 2023-03-28 | 浙江工业大学 | Composition with constipation relieving function, preparation method and equipment |
| CN115844012B (en) * | 2022-11-24 | 2024-07-26 | 浙江工业大学 | Composition with constipation relieving function, preparation method and equipment |
| CN116803300A (en) * | 2023-05-12 | 2023-09-26 | 黑龙江飞鹤乳业有限公司 | Synbiotic composition capable of improving chronic constipation symptom and preparation method and application thereof |
| CN117122002A (en) * | 2023-09-11 | 2023-11-28 | 辅农(廊坊)生物科技有限公司 | Solid beverage for improving intestinal flora and preparation method thereof |
| CN118592617A (en) * | 2024-07-31 | 2024-09-06 | 内蒙古兰格格乳业有限公司 | Composition for treating and/or improving functional constipation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111671791A (en) | Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof | |
| EP1945235B1 (en) | Probiotics to influence fat metabolism and obesity | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| US20230137618A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
| CA2893822C (en) | Strain of bifidobacterium animalis ssp. animalis | |
| CN111972670A (en) | Composition for relaxing bowel, solid beverage and application | |
| CN112402464B (en) | Compound probiotic composition beneficial to type 2diabetes patients | |
| CN111227261A (en) | Prebiotic composition and application thereof | |
| US20210008131A1 (en) | Methods for treating sarcopenia and maintaining or increasing muscle mass and muscle strength in elder subjects | |
| KR20190068078A (en) | Lactobacillus paracasei AO356 strain with Anti-Obesity Ability and Composition for treatment or improvement or preventing of obesity comprising the same | |
| KR102294445B1 (en) | Infant and child origin lactic acid bacteria Lactobacillus paracasei MG4592 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity | |
| KR102294437B1 (en) | Infant and child origin lactic acid bacteria Lactobacillus plantarum MG4553 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity | |
| CN113632841A (en) | Compound yogurt with constipation improving effect, and preparation method and application thereof | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN109221519A (en) | A kind of hypoglycemic oligosaccharide probiotics solid beverage and preparation method thereof | |
| KR102294442B1 (en) | Infant and child origin lactic acid bacteria Lactobacillus plantarum MG4555 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof | |
| KR102294451B1 (en) | Infant and child origin lactic acid bacteria Lactobacillus acidophilus MG4558 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity | |
| CN115466687B (en) | Composition for reducing body fat content and body weight and application thereof | |
| US20210401906A1 (en) | Composition for promoting defecation and uses thereof | |
| KR20220008218A (en) | Composition for preventing or treating inflammatory bowel diseases | |
| KR102077720B1 (en) | Pediococcus acidilactici AO22 strain with Anti-Obesity Ability and Composition for treatment or improvement or preventing of obesity comprising the same | |
| WO2011148221A1 (en) | Lactic acid bacteria for maturation of the enteric nervous system in infants | |
| KR102687185B1 (en) | A composition as a prebiotic for improving intestinal microflora containing polygalacturonic acid | |
| US12005090B2 (en) | Probiotic composition including lactic acid bacterial strains and use of at least one of such strains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200918 |